Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,034 across all filing types
Latest filing 2024-05-24 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Investor Presentation
Regulatory Filings
2024-05-24 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release dated May 24, 2024, announcing Glenmark Pharmaceuticals Limited's financial results for the fourth quarter and fiscal year ended March 31, 2024. It includes detailed financial data such as revenue, EBITDA, and segment-wise performance for Q4 FY 2023-24 and the full fiscal year. The document also contains a Management Discussion & Analysis (MD&A) section discussing business highlights, operational review, and strategic initiatives. The presence of comprehensive financial figures and management commentary for a quarterly period indicates this is a detailed interim/quarterly report rather than a brief earnings release or just a press announcement. The document is about 15,000 characters long, which supports it being a full report rather than a short announcement. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2024-05-24 English
Dividend Updates
Regulatory Filings
2024-05-24 English
Updates
Regulatory Filings
2024-05-24 English
Financial Result Updates
Regulatory Filings
2024-05-24 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a new marketing and distribution agreement between Glenmark Pharmaceuticals and BeiGene for oncology medicines in India. It is dated May 21, 2024, and contains no financial statements, regulatory filings, or detailed financial data. The content focuses on a business collaboration and product information rather than financial results, governance, or regulatory compliance. It is not an annual report, earnings release, management report, or any other detailed financial or regulatory document. The document is a corporate announcement about a strategic partnership and product marketing agreement, which fits best under the category of Capital/Financing Update (CAP) as it relates to a business development and commercial agreement impacting the company's operations and potential revenue streams.
2024-05-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.